Lung surfactants/mucolytics:

Indications for INFASURF:

Prevention and treatment of respiratory distress syndrome (RDS) in premature infants.


Not applicable.


See literature. Give by intratracheal administration through an endotracheal tube. 3mL/kg birth weight per dose (as 2 aliquots of 1.5mL/kg each) every 12 hours for 3 doses.


Interrupt dosing if reflux of product into endotracheal tube, cyanosis, bradycardia, airway obstruction, hypoventilation, or endotracheal tube dislodgement occurs; treat; resume after stabilization. Monitor respiratory status and clinical condition frequently and carefully.

Pharmacologic Class:

Lung surfactant.

Adverse Reactions:

Cyanosis, airway obstruction, bradycardia, reflux of surfactant into endotracheal tube, requirement for mechanical ventilation, reintubation, others.

How Supplied:

Single-use vials (6mL)—1